SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together ... - PR Newswire

SOPHiA GENETICS and Boundless Bio collaborate to develop an ecDNA detection algorithm for clinical trial enrollment in Boundless Bio's POTENTIATE Phase 1/2 study of BBI-355, an ecDNA-directed therapy for oncogene amplified cancers. Precision for Medicine supports the trial with its laboratory services, contributing to a novel workflow for patient sample processing.


Related News

SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together ... - PR Newswire

SOPHiA GENETICS and Boundless Bio collaborate to develop an ecDNA detection algorithm for clinical trial enrollment in Boundless Bio's POTENTIATE Phase 1/2 study of BBI-355, an ecDNA-directed therapy for oncogene amplified cancers. Precision for Medicine supports the trial with its laboratory services, contributing to a novel workflow for patient sample processing.

© Copyright 2024. All Rights Reserved by MedPath